

Dear Mr. Tratos,

The applicant acknowledges receipt of the Office Action dated June 24, 2019 issued in connection with Application Serial Number 88450949 for the word mark AFFINITY PLUS. Its contents have been carefully noted.

The Examining Attorney has requested that the applicant disclaim the term AFFINITY apart from the mark as filed for. Additionally, the Examining Attorney has requested that the applicant provide additional information, specifically:

1. Are the applicant's "oligonucleotides and chemicals used for their synthesis" compounds that bind specific substances? If so, what substances?
2. Are the applicant's "oligonucleotides and chemicals used for their synthesis" used to bind substances?
3. Do the applicant's "oligonucleotides and chemicals used for their synthesis" contain additional chemicals or elements other than affinity reagents? If so, what are they?
4. Do the applicant's "oligonucleotides and chemicals used for their synthesis" contain additional chemicals or elements not typically found in reagents offered by other competitors in the marketplace?
5. Do the competitors of the applicant use the wording "AFFINITY" to describe the goods they offer?

Remarks

The applicant disclaims the exclusive right to use "AFFINITY" apart from the mark as filed.

Additionally, the applicant will address each requested element individually below.

1. Synthetic oligonucleotides will hybridize (bind) to complementary oligonucleotide sequences or complementary naturally occurring nucleotide sequences.
2. Synthetic oligonucleotides will only hybridize to complementary oligonucleotide sequences or complementary naturally occurring nucleotide sequences.
3. The applicant's synthetic oligonucleotides may contain a wide variety of modifications that can be incorporated at the time of synthesis or after synthesis. For example, additional modifications may include fluorophores, modified bases, spacers, or alternative attachment chemistries and linkers. For a non-exclusive list of oligonucleotide modifications available the examiner is invited to visit Integrated DNA Technologies, Inc., at www.idtdna.com and <https://www.idtdna.com/pages/products/custom-dna-rna/oligo-modifications>.
4. The applicant's synthetic oligonucleotides may contain additional proprietary modifications. For example, IDT's Iowa Black® dark quenchers.
5. The applicant is unaware of any competitor using the wording "AFFINITY" to describe the goods it offers.

In Conclusion the applicant respectfully requests the Examiner to place the mark in condition for allowance and register the mark on the Principal Register. If the Examining Attorney wishes to speak with the applicant he is encourage to call the undersigned attorney.

Respectfully,

David Youngkin
Integrated DNA Technologies, Inc.
847-745-1687